Neuronal nicotinic receptor antagonist that displays selectivity for the α
10 subtype (IC50
values are 19, 140, 980, 4200 and 7300 nM for α
4 and α
2 subtypes respectively). Alleviates neuropathic pain in three rat models of human neuropathic pain and accelerates functional recovery of injured neurons.
(Modifications: Cys-16 - C-terminal amide, Disulfide bridge between 2 - 8, 3 - 16)
Store at -20°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license from Dr Bruce Livett
A novel α-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo.
Sandall et al.
Are α9α10 nicotinic acetylcholine receptors a pain target for α-conotoxins?
Nevin et al.
Scanning mutagenesis of α-conotoxin Vc1.1 reveals residues crucial for activity at the α9α10 nicotinic acetylcholine receptor
Halai et al.
Molecular mechanism for analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors.
Vincler et al.
The citations listed below are publications that use Tocris products. Selected citations for ACV 1 include:
Showing Results 1 - 1 of 1